Skip to main content
Erschienen in: High Blood Pressure & Cardiovascular Prevention 2/2023

03.02.2023 | Short Communication

Risk Factors Control After an Acute Coronary Syndrome and Association with Major Adverse Cardiovascular Events: A Single Center Experience in Latin-America

verfasst von: Arturo M. Ruiz-Beltran, Alejandro Alcaraz-Guzman, Diego R. Campos-Franco, Cristian D. Jimenez-Lopez, Sandra M. Ruiz-Beltran, Hilda E. Delgadillo-Rodriguez

Erschienen in: High Blood Pressure & Cardiovascular Prevention | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Abstract

Introduction

An important challenge in the secondary prevention of cardiovascular diseases is the optimization of risk factors (RFs) after hospital discharge. These have been shown to be insufficiently controlled in clinical practice.

Aim

To evaluate whether secondary prevention goals were met at our institution at 12 months after an acute coronary syndrome (ACS) index event, as well as analyzing if achieving these goals was associated with a lower incidence of major adverse cardiovascular events (MACE).

Methods

Retrospective cohort of patients with a former diagnosis of ACS over a period of 4 years. To evaluate the proportion of patients who met RF control goals at 12 months after the index event, we used two sets of preestablished goals: stringent and lenient. During follow-up we evaluated the occurrence of MACE, defined by the following: ACS, coronary revascularization, stroke, hospitalization because of acute heart failure and cardiovascular death.

Results

We included 468 patients during the study period. The mean age of the patients was 60 ± 10.76 years, 20.5% were women, and mean follow-up was 41.8 ± 22.0 months. The proportion of patients that met all secondary prevention stringent and lenient goals accounted for 5.5% and 17.2%, respectively, and 8% did not achieve any target. Overall, 9.6% presented the composite of MACE during follow-up. The number of RFs in control at 12 months was associated with a lower rate of MACE, both with stringent and lenient goals.

Conclusion

Achieving established goals for modifiable RFs can lower the incidence of MACE during long-term follow-up.
Literatur
1.
Zurück zum Zitat GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117–71.CrossRef GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117–71.CrossRef
3.
Zurück zum Zitat Martinez-Sanchez C, Borrayo G, Carrillo J, Juarez U, Quintanilla J, Jerjes-Sanchez C, et al. Clinical management and hospital outcomes of acute coronary syndrome patients in Mexico: the Third National Registry of Acute Coronary Syndromes (RENASICA III). Arch Cardiol Mex. 2016;86(3):221–32.PubMed Martinez-Sanchez C, Borrayo G, Carrillo J, Juarez U, Quintanilla J, Jerjes-Sanchez C, et al. Clinical management and hospital outcomes of acute coronary syndrome patients in Mexico: the Third National Registry of Acute Coronary Syndromes (RENASICA III). Arch Cardiol Mex. 2016;86(3):221–32.PubMed
4.
Zurück zum Zitat Chow CK, Jolly S, Rao-Melacini P, Fox KA, Anand SS, Yusuf S. Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation. 2010;121(6):750–8.PubMedCrossRef Chow CK, Jolly S, Rao-Melacini P, Fox KA, Anand SS, Yusuf S. Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation. 2010;121(6):750–8.PubMedCrossRef
5.
Zurück zum Zitat Maron DJ, Mancini GBJ, Hartigan PM, Spertus JA, Sedlis SP, Kostuk WJ, et al. Healthy behavior, risk factor control, and survival in the COURAGE trial. J Am Coll Cardiol. 2018;72(19):2297–305.PubMedCrossRef Maron DJ, Mancini GBJ, Hartigan PM, Spertus JA, Sedlis SP, Kostuk WJ, et al. Healthy behavior, risk factor control, and survival in the COURAGE trial. J Am Coll Cardiol. 2018;72(19):2297–305.PubMedCrossRef
6.
Zurück zum Zitat Bittner V, Bertolet M, Barraza Felix R, Farkouh ME, Goldberg S, Ramanathan KB, et al. Comprehensive cardiovascular risk factor control improves survival: the BARI 2D trial. J Am Coll Cardiol. 2015;66(7):765–73.PubMedPubMedCentralCrossRef Bittner V, Bertolet M, Barraza Felix R, Farkouh ME, Goldberg S, Ramanathan KB, et al. Comprehensive cardiovascular risk factor control improves survival: the BARI 2D trial. J Am Coll Cardiol. 2015;66(7):765–73.PubMedPubMedCentralCrossRef
7.
Zurück zum Zitat Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European Society of Cardiology and other societies on cardiovasular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts). Eur Heart J. 2016;37(29):2315–81.PubMedPubMedCentralCrossRef Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European Society of Cardiology and other societies on cardiovasular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts). Eur Heart J. 2016;37(29):2315–81.PubMedPubMedCentralCrossRef
8.
Zurück zum Zitat Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation. 1999;100(13):1481–92.PubMedCrossRef Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation. 1999;100(13):1481–92.PubMedCrossRef
9.
Zurück zum Zitat Pasternak RC, Grundy SM, Levy D, Thompson PD. 27th Bethesda conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 3. Spectrum of risk factors for coronary heart disease. J Am Coll Cardiol. 1996;27(5):978–90.PubMedCrossRef Pasternak RC, Grundy SM, Levy D, Thompson PD. 27th Bethesda conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 3. Spectrum of risk factors for coronary heart disease. J Am Coll Cardiol. 1996;27(5):978–90.PubMedCrossRef
10.
Zurück zum Zitat Kotseva K, De Backer G, De Bacquer D, Rydén L, Hoes A, Grobbee D, et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol. 2019;26(8):824–35.PubMedCrossRef Kotseva K, De Backer G, De Bacquer D, Rydén L, Hoes A, Grobbee D, et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol. 2019;26(8):824–35.PubMedCrossRef
11.
Zurück zum Zitat Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U, et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009;373(9667):929–40.PubMedCrossRef Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U, et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009;373(9667):929–40.PubMedCrossRef
12.
Zurück zum Zitat Lee HY, Cooke CE, Robertson TA. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge. J Manage Care Pharm. 2008;14(3):271–80. Lee HY, Cooke CE, Robertson TA. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge. J Manage Care Pharm. 2008;14(3):271–80.
13.
Zurück zum Zitat Shah ND, Dunlay SM, Ting HH, Montori VM, Thomas RJ, Wagie AE, et al. Long-term medication adherence after myocardial infarction: experience of a community. Am J Med. 2009;122(10):961.e7-13.PubMedCrossRef Shah ND, Dunlay SM, Ting HH, Montori VM, Thomas RJ, Wagie AE, et al. Long-term medication adherence after myocardial infarction: experience of a community. Am J Med. 2009;122(10):961.e7-13.PubMedCrossRef
14.
Zurück zum Zitat Du L, Cheng Z, Zhang Y, Li Y, Mei D. The impact of medication adherence on clinical outcomes of coronary artery disease: a meta-analysis. Eur J Prev Cardiol. 2017;24(9):962–70.PubMedCrossRef Du L, Cheng Z, Zhang Y, Li Y, Mei D. The impact of medication adherence on clinical outcomes of coronary artery disease: a meta-analysis. Eur J Prev Cardiol. 2017;24(9):962–70.PubMedCrossRef
15.
Zurück zum Zitat Eagle KA, Kline-Rogers E, Goodman SG, Gurfinkel EP, Avezum A, Flather MD, et al. Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. Am J Med. 2004;117(2):73–81.PubMedCrossRef Eagle KA, Kline-Rogers E, Goodman SG, Gurfinkel EP, Avezum A, Flather MD, et al. Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. Am J Med. 2004;117(2):73–81.PubMedCrossRef
16.
Zurück zum Zitat Jackevicius CA, Li P, Tu JV. Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation. 2008;117(8):1028–36.PubMedCrossRef Jackevicius CA, Li P, Tu JV. Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation. 2008;117(8):1028–36.PubMedCrossRef
17.
Zurück zum Zitat Newby LK, LaPointe NM, Chen AY, Kramer JM, Hammill BG, DeLong ER. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006;113(2):203–12.PubMedCrossRef Newby LK, LaPointe NM, Chen AY, Kramer JM, Hammill BG, DeLong ER. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006;113(2):203–12.PubMedCrossRef
18.
Zurück zum Zitat Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288(4):462–7.PubMedCrossRef Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288(4):462–7.PubMedCrossRef
19.
Zurück zum Zitat Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003;290(7):898–904.PubMedCrossRef Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003;290(7):898–904.PubMedCrossRef
20.
Zurück zum Zitat Roe MT, Halabi AR, Mehta RH, Chen AY, Newby LK, Harrington RA, et al. Documented traditional cardiovascular risk factors and mortality in non-ST-segment elevation myocardial infarction. Am Heart J. 2007;153(4):507–14.PubMedCrossRef Roe MT, Halabi AR, Mehta RH, Chen AY, Newby LK, Harrington RA, et al. Documented traditional cardiovascular risk factors and mortality in non-ST-segment elevation myocardial infarction. Am Heart J. 2007;153(4):507–14.PubMedCrossRef
21.
Zurück zum Zitat Canto JG, Kiefe CI, Rogers WJ, Peterson ED, Frederick PD, French WJ, et al. Number of coronary heart disease risk factors and mortality in patients with first myocardial infarction. JAMA. 2011;306(19):2120–7.PubMedPubMedCentralCrossRef Canto JG, Kiefe CI, Rogers WJ, Peterson ED, Frederick PD, French WJ, et al. Number of coronary heart disease risk factors and mortality in patients with first myocardial infarction. JAMA. 2011;306(19):2120–7.PubMedPubMedCentralCrossRef
22.
Zurück zum Zitat González-Pacheco H, Vargas-Barrón J, Vallejo M, Piña-Reyna Y, Altamirano-Castillo A, Sánchez-Tapia P, et al. Prevalence of conventional risk factors and lipid profiles in patients with acute coronary syndrome and significant coronary disease. Ther Clin Risk Manage. 2014;10:815–23.CrossRef González-Pacheco H, Vargas-Barrón J, Vallejo M, Piña-Reyna Y, Altamirano-Castillo A, Sánchez-Tapia P, et al. Prevalence of conventional risk factors and lipid profiles in patients with acute coronary syndrome and significant coronary disease. Ther Clin Risk Manage. 2014;10:815–23.CrossRef
23.
Zurück zum Zitat Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–337.PubMedCrossRef Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–337.PubMedCrossRef
24.
Zurück zum Zitat Martinez-Sanchez FD, Medina-Urrutia AX, Jorge-Galarza E, Martínez-Alvarado MDR, Reyes-Barrera J, Osorio-Alonso H, et al. Effect of metabolic control on recurrent major adverse cardiovascular events and cardiovascular mortality in patients with premature coronary artery disease: results of the genetics of atherosclerotic disease study. Nutr Metab Cardiovasc Dis. 2022;32(9):2227–37.PubMedCrossRef Martinez-Sanchez FD, Medina-Urrutia AX, Jorge-Galarza E, Martínez-Alvarado MDR, Reyes-Barrera J, Osorio-Alonso H, et al. Effect of metabolic control on recurrent major adverse cardiovascular events and cardiovascular mortality in patients with premature coronary artery disease: results of the genetics of atherosclerotic disease study. Nutr Metab Cardiovasc Dis. 2022;32(9):2227–37.PubMedCrossRef
25.
Zurück zum Zitat Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2017;39(2):119–77.CrossRef Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2017;39(2):119–77.CrossRef
26.
Zurück zum Zitat Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289–367.PubMedCrossRef Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289–367.PubMedCrossRef
27.
Zurück zum Zitat Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–97.PubMedCrossRef Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–97.PubMedCrossRef
28.
Zurück zum Zitat Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88.PubMedCrossRef Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88.PubMedCrossRef
29.
Zurück zum Zitat Biffi A, Gallo G, Fernando F, Sirico F, Signorello MG, Messina M, et al. Usefulness of the corporate wellness projects in primary prevention at the population level: a study on the prevalence, awareness, and control of hypertension in the Ferrari company. J Hum Hypertens. 2022;36(3):308–14.PubMedCrossRef Biffi A, Gallo G, Fernando F, Sirico F, Signorello MG, Messina M, et al. Usefulness of the corporate wellness projects in primary prevention at the population level: a study on the prevalence, awareness, and control of hypertension in the Ferrari company. J Hum Hypertens. 2022;36(3):308–14.PubMedCrossRef
30.
Zurück zum Zitat Palomo-Piñón S, Antonio-Villa NE, García-Cortés LR, Álvarez-Aguilar C, González-Palomo E, Bertadillo-Mendoza OM, et al. Prevalence and characterization of undiagnosed arterial hypertension in the eastern zone of Mexico. J Clin Hypertens (Greenwich). 2022;24(2):131–9.PubMedCrossRef Palomo-Piñón S, Antonio-Villa NE, García-Cortés LR, Álvarez-Aguilar C, González-Palomo E, Bertadillo-Mendoza OM, et al. Prevalence and characterization of undiagnosed arterial hypertension in the eastern zone of Mexico. J Clin Hypertens (Greenwich). 2022;24(2):131–9.PubMedCrossRef
31.
Zurück zum Zitat Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–104.PubMedCrossRef Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–104.PubMedCrossRef
32.
Zurück zum Zitat Salam A, Kanukula R, Atkins E, Wang X, Islam S, Kishore SP, et al. Efficacy and safety of dual combination therapy of blood pressure lowering drugs as initial treatment for hypertension: a systematic review and meta-analysis of randomized controlled trials. J Hypertens. 2019;37(9):1768–74.PubMedCrossRef Salam A, Kanukula R, Atkins E, Wang X, Islam S, Kishore SP, et al. Efficacy and safety of dual combination therapy of blood pressure lowering drugs as initial treatment for hypertension: a systematic review and meta-analysis of randomized controlled trials. J Hypertens. 2019;37(9):1768–74.PubMedCrossRef
33.
Zurück zum Zitat Egan BM, Bandyopadhyay D, Shaftman SR, Wagner CS, Zhao Y, Yu-Isenberg KS. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension. 2012;59(6):1124–31.PubMedCrossRef Egan BM, Bandyopadhyay D, Shaftman SR, Wagner CS, Zhao Y, Yu-Isenberg KS. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension. 2012;59(6):1124–31.PubMedCrossRef
34.
Zurück zum Zitat Rea F, Corrao G, Merlino L, Mancia G. Early cardiovascular protection by initial two-drug fixed-dose combination treatment vs. monotherapy in hypertension. Eur Heart J. 2018;39(40):3654–61.PubMedCrossRef Rea F, Corrao G, Merlino L, Mancia G. Early cardiovascular protection by initial two-drug fixed-dose combination treatment vs. monotherapy in hypertension. Eur Heart J. 2018;39(40):3654–61.PubMedCrossRef
35.
Zurück zum Zitat Volpe M, Gallo G, Tocci G. New approach to blood pressure control: triple combination pill. Trends Cardiovasc Med. 2020;30(2):72–7.PubMedCrossRef Volpe M, Gallo G, Tocci G. New approach to blood pressure control: triple combination pill. Trends Cardiovasc Med. 2020;30(2):72–7.PubMedCrossRef
36.
Zurück zum Zitat Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press. 2009;18(6):308–47.PubMedCrossRef Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press. 2009;18(6):308–47.PubMedCrossRef
37.
Zurück zum Zitat Gradman AH, Basile JN, Carter BL, Bakris GL. American Society of Hypertension Writing Group. Combination therapy in hypertension. J Am Soc Hypertens. 2010;4(1):42–50.PubMedCrossRef Gradman AH, Basile JN, Carter BL, Bakris GL. American Society of Hypertension Writing Group. Combination therapy in hypertension. J Am Soc Hypertens. 2010;4(1):42–50.PubMedCrossRef
38.
Zurück zum Zitat Volpe M, Gallo G, Battistoni A, Tocci G. Highlights of ESC/ESH 2018 guidelines on the management of hypertension: what every doctor should know. High Blood Press Cardiovasc Prev. 2019;26(1):1–8.PubMedCrossRef Volpe M, Gallo G, Battistoni A, Tocci G. Highlights of ESC/ESH 2018 guidelines on the management of hypertension: what every doctor should know. High Blood Press Cardiovasc Prev. 2019;26(1):1–8.PubMedCrossRef
39.
Zurück zum Zitat Choudhry NK, Patrick AR, Antman EM, Avorn J, Shrank WH. Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction medicare beneficiaries. Circulation. 2008;117(10):1261–8.PubMedPubMedCentralCrossRef Choudhry NK, Patrick AR, Antman EM, Avorn J, Shrank WH. Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction medicare beneficiaries. Circulation. 2008;117(10):1261–8.PubMedPubMedCentralCrossRef
40.
Zurück zum Zitat Choudhry NK, Avorn J, Glynn RJ, Antman EM, Schneeweiss S, Toscano M, et al. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011;365(22):2088–97.PubMedCrossRef Choudhry NK, Avorn J, Glynn RJ, Antman EM, Schneeweiss S, Toscano M, et al. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011;365(22):2088–97.PubMedCrossRef
41.
Zurück zum Zitat Ho PM, Spertus JA, Masoudi FA, Reid KJ, Peterson ED, Magid DJ, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med. 2006;166(17):1842–7.PubMedCrossRef Ho PM, Spertus JA, Masoudi FA, Reid KJ, Peterson ED, Magid DJ, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med. 2006;166(17):1842–7.PubMedCrossRef
42.
Zurück zum Zitat Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297(2):177–86.PubMedCrossRef Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297(2):177–86.PubMedCrossRef
43.
Zurück zum Zitat Yue Z, Cai C, Ai-Fang Y, Feng-Min T, Li C, Bin W. The effect of placebo adherence on reducing cardiovascular mortality: a meta-analysis. Clin Res Cardiol. 2014;103(3):229–35.PubMedCrossRef Yue Z, Cai C, Ai-Fang Y, Feng-Min T, Li C, Bin W. The effect of placebo adherence on reducing cardiovascular mortality: a meta-analysis. Clin Res Cardiol. 2014;103(3):229–35.PubMedCrossRef
Metadaten
Titel
Risk Factors Control After an Acute Coronary Syndrome and Association with Major Adverse Cardiovascular Events: A Single Center Experience in Latin-America
verfasst von
Arturo M. Ruiz-Beltran
Alejandro Alcaraz-Guzman
Diego R. Campos-Franco
Cristian D. Jimenez-Lopez
Sandra M. Ruiz-Beltran
Hilda E. Delgadillo-Rodriguez
Publikationsdatum
03.02.2023
Verlag
Springer International Publishing
Erschienen in
High Blood Pressure & Cardiovascular Prevention / Ausgabe 2/2023
Print ISSN: 1120-9879
Elektronische ISSN: 1179-1985
DOI
https://doi.org/10.1007/s40292-023-00560-x

Weitere Artikel der Ausgabe 2/2023

High Blood Pressure & Cardiovascular Prevention 2/2023 Zur Ausgabe

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.